Measuring Parkinson's Disease Progression
| Status: | Recruiting |
|---|---|
| Conditions: | Parkinsons Disease |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 40 - 79 |
| Updated: | 3/28/2019 |
| Start Date: | October 19, 2017 |
| End Date: | September 30, 2019 |
| Contact: | Kevin J Black, MD |
| Email: | kevin@WUSTL.edu |
| Phone: | 3143625041 |
Dopamine Buffering Capacity Measured by phMRI as a Novel Biomarker of Disease Progression in PD
The Measuring Parkinson's Disease Progression study aims to use MRI scans and a controlled
dose of levodopa to find a biomarker (objective measurement) of Parkinson's disease (PD).
Biomarkers would help determine the effectiveness of therapies in slowing or stopping PD
progression, and accelerate the pace of research.
dose of levodopa to find a biomarker (objective measurement) of Parkinson's disease (PD).
Biomarkers would help determine the effectiveness of therapies in slowing or stopping PD
progression, and accelerate the pace of research.
Early in the course of Parkinson's disease, a small dose of levodopa (L-DOPA) provides
benefit for many hours. The body responds as if the levodopa in the plasma filled a reservoir
and then slowly leaked out to produce benefit. With disease progression, even though the same
amount of levodopa circulates in the blood, the benefit wears off much faster, as if the
reservoir had become leakier. This wearing off of benefit can be characterized by a single
number, the effect site rate constant Ke. On average, patients with more severe disease and
longer disease duration have a larger ("leakier") Ke when the response to drug is measured
using clinical features like tapping speed. Unfortunately, clinical measurements are
influenced by confounding factors such as patient fatigue and comfort. A direct, objective
brain measure of response to levodopa may improve the reliability of this measurement.
Fortunately, we can assess the effect of levodopa on the brain directly, using an MRI machine
to measure blood flow in different parts of the brain. For instance, the midbrain has a
robust blood flow response to a single, clinically sensible dose of levodopa. This study's
goal is to validate MRI measurement of Ke in the brain as an objective, quantitative measure
of disease severity in PD. We will do this by comparing MRI-based Ke values from people with
PD across a wide range of disease duration and severity. In a subgroup of participants, we
will do this measurement twice, once before treatment and once after 6 weeks of treatment
with carbidopa-levodopa (Sinemet® and other brand names).
benefit for many hours. The body responds as if the levodopa in the plasma filled a reservoir
and then slowly leaked out to produce benefit. With disease progression, even though the same
amount of levodopa circulates in the blood, the benefit wears off much faster, as if the
reservoir had become leakier. This wearing off of benefit can be characterized by a single
number, the effect site rate constant Ke. On average, patients with more severe disease and
longer disease duration have a larger ("leakier") Ke when the response to drug is measured
using clinical features like tapping speed. Unfortunately, clinical measurements are
influenced by confounding factors such as patient fatigue and comfort. A direct, objective
brain measure of response to levodopa may improve the reliability of this measurement.
Fortunately, we can assess the effect of levodopa on the brain directly, using an MRI machine
to measure blood flow in different parts of the brain. For instance, the midbrain has a
robust blood flow response to a single, clinically sensible dose of levodopa. This study's
goal is to validate MRI measurement of Ke in the brain as an objective, quantitative measure
of disease severity in PD. We will do this by comparing MRI-based Ke values from people with
PD across a wide range of disease duration and severity. In a subgroup of participants, we
will do this measurement twice, once before treatment and once after 6 weeks of treatment
with carbidopa-levodopa (Sinemet® and other brand names).
Inclusion Criteria:
- Age 40-79 at screening
- Meet accepted diagnostic criteria for Parkinson disease
Exclusion Criteria: Key exclusion criteria:
- Deep brain stimulator (DBS)
- Pregnancy
- Patients taking a dopamine antagonist (like quetiapine) or dopamine partial agonist
(like aripiprazole)
- Metal in the head or eye, or other contraindication to MRI
- Claustrophobia
- Serious neurologic disease other than PD
- Head trauma with loss of consciousness for more than 5 minutes
- Severe or unstable systemic illness
- Certain psychiatric illnesses (dementia, psychosis, current major depression)
- Current alcohol use disorder
- Subjects who feel that going without nicotine for 3-4 hours would be uncomfortable
- Currently taking an extended-release formulation of a dopamine agonist (like Mirapex
ER or Requip XL)
We found this trial at
1
site
517 South Euclid Avenue
Saint Louis, Missouri 63110
Saint Louis, Missouri 63110
Principal Investigator: Kevin J. Black, MD
Phone: 314-362-2083
Click here to add this to my saved trials
